The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in practicaldermatology.com
A new approach that integrates a minimally invasive, painless microneedle platform may help monitor protein biomarkers in responses to a combination immunotherapy against melanoma.
The platform is capable of absorbing the cell-surrounding, biomarker-containing fluid from deeper layers of the skin with an ultra-sensitive, single-molecule detection method (Simoa) that detects often rare, yet relevant biomarkers with higher sensitivity than conventional methods.
The researchers provided proof-of-concept for their approach in a mouse melanoma model in which they treated cancerous lesions with a novel therapy. The therapy acts locally on tumor lesions in that it combines non-invasive focused ultrasound (FUS), which generates heat at the tumor site to instantly kill tumor cells, with the delivery of a previously developed nanoparticle-bound activator of an inflammation-inducing protein known as stimulator of interferon genes (STING).
The co-author of this research is Technion Professor Haim Azhari.